1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Vaccine Conjugate Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Hib Vaccine 1.2.3 Meningococcal Vaccine 1.2.4 Pneumococcal Vaccine 1.2.5 Others 1.3 Market Segment by Application 1.3.1 Global Vaccine Conjugate Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Children 1.3.3 Adult 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Vaccine Conjugate Market Size (2017-2028) 2.1.1 Global Vaccine Conjugate Revenue (2017-2028) 2.1.2 Global Vaccine Conjugate Sales (2017-2028) 2.2 Global Vaccine Conjugate Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Vaccine Conjugate Sales by Regions (2017-2022) 2.2.2 Global Vaccine Conjugate Revenue by Regions (2017-2022) 2.3 Global Vaccine Conjugate Market Size Forecast by Region 2.3.1 Global Vaccine Conjugate Sales Forecast by Region (2023-2028) 2.3.2 Global Vaccine Conjugate Revenue Forecast by Region (2023-2028) 2.4 Global Top Vaccine Conjugate Regions (Countries) Ranking by Market Size 2.5 Vaccine Conjugate Market Dynamics 2.5.1 Vaccine Conjugate Market Trends 2.5.2 Vaccine Conjugate Market Drivers 2.5.3 Vaccine Conjugate Market Challenges 2.5.4 Vaccine Conjugate Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Vaccine Conjugate Manufacturers by Sales (2017-2022) 3.1.1 Global Vaccine Conjugate Sales by Manufacturers (2017-2022) 3.1.2 Global Vaccine Conjugate Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Vaccine Conjugate Sales in 2021 3.2 Global Top Manufacturers Vaccine Conjugate by Revenue 3.2.1 Global Vaccine Conjugate Revenue by Manufacturers (2017-2022) 3.2.2 Top Vaccine Conjugate Manufacturers Covered: Ranking by Revenue 3.2.3 Global Vaccine Conjugate Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Vaccine Conjugate Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Conjugate as of 2021) 3.4 Global Vaccine Conjugate Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Vaccine Conjugate Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Vaccine Conjugate Market 3.7 Key Manufacturers Vaccine Conjugate Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Vaccine Conjugate Market Size by Type 4.1 Global Vaccine Conjugate Historic Market Review by Type (2017-2022) 4.1.1 Global Vaccine Conjugate Sales Market Share by Type (2017-2022) 4.1.2 Global Vaccine Conjugate Revenue Market Share by Type (2017-2022) 4.1.3 Vaccine Conjugate Price by Type (2017-2022) 4.2 Global Vaccine Conjugate Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Vaccine Conjugate Sales Forecast by Type (2023-2028) 4.2.2 Global Vaccine Conjugate Revenue Forecast by Type (2023-2028) 4.2.3 Vaccine Conjugate Price Forecast by Type (2023-2028) 5 Global Vaccine Conjugate Market Size by Application 5.1 Global Vaccine Conjugate Historic Market Review by Application (2017-2022) 5.1.1 Global Vaccine Conjugate Sales Market Share by Application (2017-2022) 5.1.2 Global Vaccine Conjugate Revenue Market Share by Application (2017-2022) 5.1.3 Vaccine Conjugate Price by Application (2017-2022) 5.2 Global Vaccine Conjugate Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Vaccine Conjugate Sales Forecast by Application (2023-2028) 5.2.2 Global Vaccine Conjugate Revenue Forecast by Application (2023-2028) 5.2.3 Vaccine Conjugate Price Forecast by Application (2023-2028) 6 North America 6.1 North America Vaccine Conjugate Sales Breakdown by Company 6.1.1 North America Vaccine Conjugate Sales by Company (2017-2022) 6.1.2 North America Vaccine Conjugate Revenue by Company (2017-2022) 6.2 North America Vaccine Conjugate Market Size by Type 6.2.1 North America Vaccine Conjugate Sales by Type (2017-2028) 6.2.2 North America Vaccine Conjugate Revenue by Type (2017-2028) 6.3 North America Vaccine Conjugate Market Size by Application 6.3.1 North America Vaccine Conjugate Sales by Application (2017-2028) 6.3.2 North America Vaccine Conjugate Revenue by Application (2017-2028) 6.4 North America Vaccine Conjugate Market Size by Country 6.4.1 North America Vaccine Conjugate Sales by Country (2017-2028) 6.4.2 North America Vaccine Conjugate Revenue by Country (2017-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Vaccine Conjugate Sales Breakdown by Company 7.1.1 Europe Vaccine Conjugate Sales by Company (2017-2022) 7.1.2 Europe Vaccine Conjugate Revenue by Company (2017-2022) 7.2 Europe Vaccine Conjugate Market Size by Type 7.2.1 Europe Vaccine Conjugate Sales by Type (2017-2028) 7.2.2 Europe Vaccine Conjugate Revenue by Type (2017-2028) 7.3 Europe Vaccine Conjugate Market Size by Application 7.3.1 Europe Vaccine Conjugate Sales by Application (2017-2028) 7.3.2 Europe Vaccine Conjugate Revenue by Application (2017-2028) 7.4 Europe Vaccine Conjugate Market Size by Country 7.4.1 Europe Vaccine Conjugate Sales by Country (2017-2028) 7.4.2 Europe Vaccine Conjugate Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Vaccine Conjugate Sales Breakdown by Company 8.1.1 Asia Pacific Vaccine Conjugate Sales by Company (2017-2022) 8.1.2 Asia Pacific Vaccine Conjugate Revenue by Company (2017-2022) 8.2 Asia Pacific Vaccine Conjugate Market Size by Type 8.2.1 Asia Pacific Vaccine Conjugate Sales by Type (2017-2028) 8.2.2 Asia Pacific Vaccine Conjugate Revenue by Type (2017-2028) 8.3 Asia Pacific Vaccine Conjugate Market Size by Application 8.3.1 Asia Pacific Vaccine Conjugate Sales by Application (2017-2028) 8.3.2 Asia Pacific Vaccine Conjugate Revenue by Application (2017-2028) 8.4 Asia Pacific Vaccine Conjugate Market Size by Region 8.4.1 Asia Pacific Vaccine Conjugate Sales by Region 8.4.2 Asia Pacific Vaccine Conjugate Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 Taiwan 8.4.9 Indonesia 8.4.10 Thailand 8.4.11 Malaysia 8.4.12 Philippines 8.4.13 Vietnam 9 Latin America 9.1 Latin America Vaccine Conjugate Sales Breakdown by Company 9.1.1 Latin America Vaccine Conjugate Sales by Company (2017-2022) 9.1.2 Latin America Vaccine Conjugate Revenue by Company (2017-2022) 9.2 Latin America Vaccine Conjugate Market Size by Type 9.2.1 Latin America Vaccine Conjugate Sales by Type (2017-2028) 9.2.2 Latin America Vaccine Conjugate Revenue by Type (2017-2028) 9.3 Latin America Vaccine Conjugate Market Size by Application 9.3.1 Latin America Vaccine Conjugate Sales by Application (2017-2028) 9.3.2 Latin America Vaccine Conjugate Revenue by Application (2017-2028) 9.4 Latin America Vaccine Conjugate Market Size by Country 9.4.1 Latin America Vaccine Conjugate Sales by Country (2017-2028) 9.4.2 Latin America Vaccine Conjugate Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Vaccine Conjugate Sales Breakdown by Company 10.1.1 Middle East and Africa Vaccine Conjugate Sales by Company (2017-2022) 10.1.2 Middle East and Africa Vaccine Conjugate Revenue by Company (2017-2022) 10.2 Middle East and Africa Vaccine Conjugate Market Size by Type 10.2.1 Middle East and Africa Vaccine Conjugate Sales by Type (2017-2028) 10.2.2 Middle East and Africa Vaccine Conjugate Revenue by Type (2017-2028) 10.3 Middle East and Africa Vaccine Conjugate Market Size by Application 10.3.1 Middle East and Africa Vaccine Conjugate Sales by Application (2017-2028) 10.3.2 Middle East and Africa Vaccine Conjugate Revenue by Application (2017-2028) 10.4 Middle East and Africa Vaccine Conjugate Market Size by Country 10.4.1 Middle East and Africa Vaccine Conjugate Sales by Country (2017-2028) 10.4.2 Middle East and Africa Vaccine Conjugate Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 U.A.E 11 Company Profiles 11.1 Pfizer 11.1.1 Pfizer Corporation Information 11.1.2 Pfizer Overview 11.1.3 Pfizer Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 Pfizer Vaccine Conjugate Products and Services 11.1.5 Pfizer Vaccine Conjugate SWOT Analysis 11.1.6 Pfizer Recent Developments 11.2 GSK 11.2.1 GSK Corporation Information 11.2.2 GSK Overview 11.2.3 GSK Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 GSK Vaccine Conjugate Products and Services 11.2.5 GSK Vaccine Conjugate SWOT Analysis 11.2.6 GSK Recent Developments 11.3 Sanofi 11.3.1 Sanofi Corporation Information 11.3.2 Sanofi Overview 11.3.3 Sanofi Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 Sanofi Vaccine Conjugate Products and Services 11.3.5 Sanofi Vaccine Conjugate SWOT Analysis 11.3.6 Sanofi Recent Developments 11.4 Merck 11.4.1 Merck Corporation Information 11.4.2 Merck Overview 11.4.3 Merck Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Merck Vaccine Conjugate Products and Services 11.4.5 Merck Vaccine Conjugate SWOT Analysis 11.4.6 Merck Recent Developments 11.5 Walvax Biotechnology 11.5.1 Walvax Biotechnology Corporation Information 11.5.2 Walvax Biotechnology Overview 11.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Walvax Biotechnology Vaccine Conjugate Products and Services 11.5.5 Walvax Biotechnology Vaccine Conjugate SWOT Analysis 11.5.6 Walvax Biotechnology Recent Developments 11.6 Royal (Wuxi) Bio-Pharmaceutical 11.6.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information 11.6.2 Royal (Wuxi) Bio-Pharmaceutical Overview 11.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.6.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Products and Services 11.6.5 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate SWOT Analysis 11.6.6 Royal (Wuxi) Bio-Pharmaceutical Recent Developments 11.7 Bharat Biotech 11.7.1 Bharat Biotech Corporation Information 11.7.2 Bharat Biotech Overview 11.7.3 Bharat Biotech Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.7.4 Bharat Biotech Vaccine Conjugate Products and Services 11.7.5 Bharat Biotech Vaccine Conjugate SWOT Analysis 11.7.6 Bharat Biotech Recent Developments 11.8 Zhifei Biologic 11.8.1 Zhifei Biologic Corporation Information 11.8.2 Zhifei Biologic Overview 11.8.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.8.4 Zhifei Biologic Vaccine Conjugate Products and Services 11.8.5 Zhifei Biologic Vaccine Conjugate SWOT Analysis 11.8.6 Zhifei Biologic Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Vaccine Conjugate Value Chain Analysis 12.2 Vaccine Conjugate Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Vaccine Conjugate Production Mode & Process 12.4 Vaccine Conjugate Sales and Marketing 12.4.1 Vaccine Conjugate Sales Channels 12.4.2 Vaccine Conjugate Distributors 12.5 Vaccine Conjugate Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Vaccine Conjugate Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Hib Vaccine Table 3. Major Manufacturers of Meningococcal Vaccine Table 4. Major Manufacturers of Pneumococcal Vaccine Table 5. Major Manufacturers of Others Table 6. Global Vaccine Conjugate Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 7. Global Vaccine Conjugate Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 8. Global Vaccine Conjugate Sales by Region (2017-2022) & (K Doses) Table 9. Global Vaccine Conjugate Sales Market Share by Region (2017-2022) Table 10. Global Vaccine Conjugate Revenue by Region (2017-2022) & (US$ Million) Table 11. Global Vaccine Conjugate Revenue Market Share by Region (2017-2022) Table 12. Global Vaccine Conjugate Sales Forecast by Region (2023-2028) & (K Doses) Table 13. Global Vaccine Conjugate Sales Market Share Forecast by Region (2023-2028) Table 14. Global Vaccine Conjugate Revenue Forecast by Region (2023-2028) & (US$ Million) Table 15. Global Vaccine Conjugate Revenue Market Share Forecast by Region (2023-2028) Table 16. Top Vaccine Conjugate Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 17. Vaccine Conjugate Market Trends Table 18. Vaccine Conjugate Market Drivers Table 19. Vaccine Conjugate Market Challenges Table 20. Vaccine Conjugate Market Restraints Table 21. Global Vaccine Conjugate Sales by Manufacturers (2017-2022) & (K Doses) Table 22. Global Vaccine Conjugate Sales Share by Manufacturers (2017-2022) Table 23. Global Vaccine Conjugate Revenue by Manufacturers (2017-2022) & (US$ Million) Table 24. Ranking of Global Top Vaccine Conjugate Manufacturers by Revenue (US$ Million) in 2021 Table 25. Vaccine Conjugate Revenue Share by Manufacturers (2017-2022) Table 26. Global Vaccine Conjugate Manufacturers Market Concentration Ratio (CR5 and HHI) Table 27. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Conjugate as of 2021) Table 28. Key Manufacturers Vaccine Conjugate Average Selling Price (ASP) & (2017-2022) & (USD/Dose) Table 29. Key Manufacturers Vaccine Conjugate Plants/Factories Distribution Table 30. Key Manufacturers Vaccine Conjugate Area Served Table 31. Date of Key Manufacturers Enter into Vaccine Conjugate Market Table 32. Key Manufacturers Vaccine Conjugate Product Type Table 33. Mergers & Acquisitions, Expansion Plans Table 34. Global Vaccine Conjugate Sales (K Doses) by Type (2017-2022) Table 35. Global Vaccine Conjugate Sales Share by Type (2017-2022) Table 36. Global Vaccine Conjugate Revenue (US$ Million) Market Share by Type (2017-2022) Table 37. Global Vaccine Conjugate Price (K Doses) by Type (2017-2022) Table 38. Global Vaccine Conjugate Sales (K Doses) by Type (2023-2028) Table 39. Global Vaccine Conjugate Sales Share by Type (2023-2028) Table 40. Global Vaccine Conjugate Revenue (US$ Million) Market Share by Type (2023-2028) Table 41. Global Vaccine Conjugate Revenue Share by Type (2023-2028) Table 42. Global Vaccine Conjugate Price (K Doses) by Type (2023-2028) Table 43. Global Vaccine Conjugate Sales (K Doses) by Application (2017-2022) Table 44. Global Vaccine Conjugate Sales Share by Application (2017-2022) Table 45. Global Vaccine Conjugate Revenue (US$ Million) Market Share by Application (2017-2022) Table 46. Global Vaccine Conjugate Price (K Doses) by Application (2017-2022) Table 47. Global Vaccine Conjugate Sales (K Doses) by Application (2023-2028) Table 48. Global Vaccine Conjugate Sales Share by Application (2023-2028) Table 49. Global Vaccine Conjugate Revenue (US$ Million) Market Share by Application (2023-2028) Table 50. Global Vaccine Conjugate Revenue Share by Application (2023-2028) Table 51. Global Vaccine Conjugate Price (K Doses) by Application (2023-2028) Table 52. North America Vaccine Conjugate Sales by Company (2017-2022) & (K Doses) Table 53. North America Vaccine Conjugate Sales Market Share by Company (2017-2022) Table 54. North America Vaccine Conjugate Revenue by Company (2017-2022) & (US$ Million) Table 55. North America Vaccine Conjugate Revenue Market Share by Company (2017-2022) Table 56. North America Vaccine Conjugate Sales by Type (2017-2022) & (K Doses) Table 57. North America Vaccine Conjugate Sales by Type (2023-2028) & (K Doses) Table 58. North America Vaccine Conjugate Revenue by Type (2017-2022) & (US$ Million) Table 59. North America Vaccine Conjugate Revenue by Type (2023-2028) & (US$ Million) Table 60. North America Vaccine Conjugate Sales by Application (2017-2022) & (K Doses) Table 61. North America Vaccine Conjugate Sales by Application (2023-2028) & (K Doses) Table 62. North America Vaccine Conjugate Revenue by Application (2017-2022) & (US$ Million) Table 63. North America Vaccine Conjugate Revenue by Application (2023-2028) & (US$ Million) Table 64. North America Vaccine Conjugate Sales by Country (2017-2022) & (K Doses) Table 65. North America Vaccine Conjugate Sales by Country (2023-2028) & (K Doses) Table 66. North America Vaccine Conjugate Revenue by Country (2017-2022) & (US$ Million) Table 67. North America Vaccine Conjugate Revenue by Country (2023-2028) & (US$ Million) Table 68. Europe Vaccine Conjugate Sales by Company (2017-2022) & (K Doses) Table 69. Europe Vaccine Conjugate Sales Market Share by Company (2017-2022) Table 70. Europe Vaccine Conjugate Revenue by Company (2017-2022) & (US$ Million) Table 71. Europe Vaccine Conjugate Revenue Market Share by Company (2017-2022) Table 72. Europe Vaccine Conjugate Sales by Type (2017-2022) & (K Doses) Table 73. Europe Vaccine Conjugate Sales by Type (2023-2028) & (K Doses) Table 74. Europe Vaccine Conjugate Revenue by Type (2017-2022) & (US$ Million) Table 75. Europe Vaccine Conjugate Revenue by Type (2023-2028) & (US$ Million) Table 76. Europe Vaccine Conjugate Sales by Application (2017-2022) & (K Doses) Table 77. Europe Vaccine Conjugate Sales by Application (2023-2028) & (K Doses) Table 78. Europe Vaccine Conjugate Revenue by Application (2017-2022) & (US$ Million) Table 79. Europe Vaccine Conjugate Revenue by Application (2023-2028) & (US$ Million) Table 80. Europe Vaccine Conjugate Sales by Country (2017-2022) & (K Doses) Table 81. Europe Vaccine Conjugate Sales by Country (2023-2028) & (K Doses) Table 82. Europe Vaccine Conjugate Revenue by Country (2017-2022) & (US$ Million) Table 83. Europe Vaccine Conjugate Revenue by Country (2023-2028) & (US$ Million) Table 84. Asia Pacific Vaccine Conjugate Sales by Company (2017-2022) & (K Doses) Table 85. Asia Pacific Vaccine Conjugate Sales Market Share by Company (2017-2022) Table 86. Asia Pacific Vaccine Conjugate Revenue by Company (2017-2022) & (US$ Million) Table 87. Asia Pacific Vaccine Conjugate Revenue Market Share by Company (2017-2022) Table 88. Asia Pacific Vaccine Conjugate Sales by Type (2017-2022) & (K Doses) Table 89. Asia Pacific Vaccine Conjugate Sales by Type (2023-2028) & (K Doses) Table 90. Asia Pacific Vaccine Conjugate Revenue by Type (2017-2022) & (US$ Million) Table 91. Asia Pacific Vaccine Conjugate Revenue by Type (2023-2028) & (US$ Million) Table 92. Asia Pacific Vaccine Conjugate Sales by Application (2017-2022) & (K Doses) Table 93. Asia Pacific Vaccine Conjugate Sales by Application (2023-2028) & (K Doses) Table 94. Asia Pacific Vaccine Conjugate Revenue by Application (2017-2022) & (US$ Million) Table 95. Asia Pacific Vaccine Conjugate Revenue by Application (2023-2028) & (US$ Million) Table 96. Asia Pacific Vaccine Conjugate Sales by Region (2017-2022) & (K Doses) Table 97. Asia Pacific Vaccine Conjugate Sales by Region (2023-2028) & (K Doses) Table 98. Asia Pacific Vaccine Conjugate Revenue by Region (2017-2022) & (US$ Million) Table 99. Asia Pacific Vaccine Conjugate Revenue by Region (2023-2028) & (US$ Million) Table 100. Latin America Vaccine Conjugate Sales by Company (2017-2022) & (K Doses) Table 101. Latin America Vaccine Conjugate Sales Market Share by Company (2017-2022) Table 102. Latin America Vaccine Conjugate Revenue by Company (2017-2022) & (US$ Million) Table 103. Latin America Vaccine Conjugate Revenue Market Share by Company (2017-2022) Table 104. Latin America Vaccine Conjugate Sales by Type (2017-2022) & (K Doses) Table 105. Latin America Vaccine Conjugate Sales by Type (2023-2028) & (K Doses) Table 106. Latin America Vaccine Conjugate Revenue by Type (2017-2022) & (US$ Million) Table 107. Latin America Vaccine Conjugate Revenue by Type (2023-2028) & (US$ Million) Table 108. Latin America Vaccine Conjugate Sales by Application (2017-2022) & (K Doses) Table 109. Latin America Vaccine Conjugate Sales by Application (2023-2028) & (K Doses) Table 110. Latin America Vaccine Conjugate Revenue by Application (2017-2022) & (US$ Million) Table 111. Latin America Vaccine Conjugate Revenue by Application (2023-2028) & (US$ Million) Table 112. Latin America Vaccine Conjugate Sales by Country (2017-2022) & (K Doses) Table 113. Latin America Vaccine Conjugate Sales by Country (2023-2028) & (K Doses) Table 114. Latin America Vaccine Conjugate Revenue by Country (2017-2022) & (US$ Million) Table 115. Latin America Vaccine Conjugate Revenue by Country (2023-2028) & (US$ Million) Table 116. Middle East and Africa Vaccine Conjugate Sales by Company (2017-2022) & (K Doses) Table 117. Middle East and Africa Vaccine Conjugate Sales Market Share by Company (2017-2022) Table 118. Middle East and Africa Vaccine Conjugate Revenue by Company (2017-2022) & (US$ Million) Table 119. Middle East and Africa Vaccine Conjugate Revenue Market Share by Company (2017-2022) Table 120. Middle East and Africa Vaccine Conjugate Sales by Type (2017-2022) & (K Doses) Table 121. Middle East and Africa Vaccine Conjugate Sales by Type (2023-2028) & (K Doses) Table 122. Middle East and Africa Vaccine Conjugate Revenue by Type (2017-2022) & (US$ Million) Table 123. Middle East and Africa Vaccine Conjugate Revenue by Type (2023-2028) & (US$ Million) Table 124. Middle East and Africa Vaccine Conjugate Sales by Application (2017-2022) & (K Doses) Table 125. Middle East and Africa Vaccine Conjugate Sales by Application (2023-2028) & (K Doses) Table 126. Middle East and Africa Vaccine Conjugate Revenue by Application (2017-2022) & (US$ Million) Table 127. Middle East and Africa Vaccine Conjugate Revenue by Application (2023-2028) & (US$ Million) Table 128. Middle East and Africa Vaccine Conjugate Sales by Country (2017-2022) & (K Doses) Table 129. Middle East and Africa Vaccine Conjugate Sales by Country (2023-2028) & (K Doses) Table 130. Middle East and Africa Vaccine Conjugate Revenue by Country (2017-2022) & (US$ Million) Table 131. Middle East and Africa Vaccine Conjugate Revenue by Country (2023-2028) & (US$ Million) Table 132. Pfizer Corporation Information Table 133. Pfizer Description and Overview Table 134. Pfizer Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 135. Pfizer Vaccine Conjugate Product and Services Table 136. Pfizer Vaccine Conjugate SWOT Analysis Table 137. Pfizer Recent Developments Table 138. GSK Corporation Information Table 139. GSK Description and Overview Table 140. GSK Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 141. GSK Vaccine Conjugate Product and Services Table 142. GSK Vaccine Conjugate SWOT Analysis Table 143. GSK Recent Developments Table 144. Sanofi Corporation Information Table 145. Sanofi Description and Overview Table 146. Sanofi Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 147. Sanofi Vaccine Conjugate Product and Services Table 148. Sanofi Vaccine Conjugate SWOT Analysis Table 149. Sanofi Recent Developments Table 150. Merck Corporation Information Table 151. Merck Description and Overview Table 152. Merck Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 153. Merck Vaccine Conjugate Product and Services Table 154. Merck Vaccine Conjugate SWOT Analysis Table 155. Merck Recent Developments Table 156. Walvax Biotechnology Corporation Information Table 157. Walvax Biotechnology Description and Overview Table 158. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 159. Walvax Biotechnology Vaccine Conjugate Product and Services Table 160. Walvax Biotechnology Vaccine Conjugate SWOT Analysis Table 161. Walvax Biotechnology Recent Developments Table 162. Royal (Wuxi) Bio-Pharmaceutical Corporation Information Table 163. Royal (Wuxi) Bio-Pharmaceutical Description and Overview Table 164. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 165. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product and Services Table 166. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate SWOT Analysis Table 167. Royal (Wuxi) Bio-Pharmaceutical Recent Developments Table 168. Bharat Biotech Corporation Information Table 169. Bharat Biotech Description and Overview Table 170. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 171. Bharat Biotech Vaccine Conjugate Product and Services Table 172. Bharat Biotech Vaccine Conjugate SWOT Analysis Table 173. Bharat Biotech Recent Developments Table 174. Zhifei Biologic Corporation Information Table 175. Zhifei Biologic Description and Overview Table 176. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2017-2022) Table 177. Zhifei Biologic Vaccine Conjugate Product and Services Table 178. Zhifei Biologic Vaccine Conjugate SWOT Analysis Table 179. Zhifei Biologic Recent Developments Table 180. Key Raw Materials Lists Table 181. Raw Materials Key Suppliers Lists Table 182. Vaccine Conjugate Distributors List Table 183. Vaccine Conjugate Customers List Table 184. Research Programs/Design for This Report Table 185. Key Data Information from Secondary Sources Table 186. Key Data Information from Primary Sources List of Figures Figure 1. Vaccine Conjugate Product Picture Figure 2. Global Vaccine Conjugate Sales Market Share by Type in 2021 & 2028 Figure 3. Hib Vaccine Product Picture Figure 4. Meningococcal Vaccine Product Picture Figure 5. Pneumococcal Vaccine Product Picture Figure 6. Others Product Picture Figure 7. Global Vaccine Conjugate Sales Market Share by Application in 2021 & 2028 Figure 8. Children Use Case Figure 9. Adult Use Case Figure 10. Vaccine Conjugate Report Years Considered Figure 11. Global Vaccine Conjugate Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Vaccine Conjugate Market Size 2017-2028 (US$ Million) Figure 13. Global Vaccine Conjugate Sales (2017-2022) & (K Doses) Figure 14. Global Vaccine Conjugate Market Size Market Share by Region: 2021 VS 2028 Figure 15. Global Vaccine Conjugate Sales Market Share by Region (2017-2022) Figure 16. Global Vaccine Conjugate Sales Market Share by Region in 2021 Figure 17. Global Vaccine Conjugate Revenue Market Share by Region in 2017 VS 2021 Figure 18. Global Vaccine Conjugate Sales Share by Manufacturers in 2021 Figure 19. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine Conjugate Sales in 2021 Figure 20. Vaccine Conjugate Revenue Share by Manufacturers in 2021 Figure 21. Vaccine Conjugate Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 22. Global Vaccine Conjugate Revenue Share by Type (2017-2022) Figure 23. Global Vaccine Conjugate Revenue Growth Rate by Type in 2017 & 2021 Figure 24. Global Vaccine Conjugate Revenue Share by Application (2017-2022) Figure 25. Global Vaccine Conjugate Revenue Growth Rate by Application in 2017 & 2021 Figure 26. North America Vaccine Conjugate Sales Market Share by Type (2017-2028) Figure 27. North America Vaccine Conjugate Revenue Market Share by Type (2017-2028) Figure 28. North America Vaccine Conjugate Sales Market Share by Application (2017-2028) Figure 29. North America Vaccine Conjugate Revenue Market Share by Application (2017-2028) Figure 30. North America Vaccine Conjugate Sales Share by Country (2017-2028) Figure 31. North America Vaccine Conjugate Revenue Share by Country (2017-2028) Figure 32. U.S. Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 33. Canada Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 34. Europe Vaccine Conjugate Sales Market Share by Type (2017-2028) Figure 35. Europe Vaccine Conjugate Revenue Market Share by Type (2017-2028) Figure 36. Europe Vaccine Conjugate Sales Market Share by Application (2017-2028) Figure 37. Europe Vaccine Conjugate Revenue Market Share by Application (2017-2028) Figure 38. Europe Vaccine Conjugate Sales Share by Country (2017-2028) Figure 39. Europe Vaccine Conjugate Revenue Share by Country (2017-2028) Figure 40. Germany Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 41. France Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 42. U.K. Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 43. Italy Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 44. Russia Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 45. Asia Pacific Vaccine Conjugate Sales Market Share by Type (2017-2028) Figure 46. Asia Pacific Vaccine Conjugate Revenue Market Share by Type (2017-2028) Figure 47. Asia Pacific Vaccine Conjugate Sales Market Share by Application (2017-2028) Figure 48. Asia Pacific Vaccine Conjugate Revenue Market Share by Application (2017-2028) Figure 49. Asia Pacific Vaccine Conjugate Sales Share by Region (2017-2028) Figure 50. Asia Pacific Vaccine Conjugate Revenue Share by Region (2017-2028) Figure 51. China Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 52. Japan Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 53. South Korea Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 54. India Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 55. Australia Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 56. Taiwan Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 57. Indonesia Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 58. Thailand Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 59. Malaysia Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 60. Philippines Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 61. Vietnam Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 62. Latin America Vaccine Conjugate Sales Market Share by Type (2017-2028) Figure 63. Latin America Vaccine Conjugate Revenue Market Share by Type (2017-2028) Figure 64. Latin America Vaccine Conjugate Sales Market Share by Application (2017-2028) Figure 65. Latin America Vaccine Conjugate Revenue Market Share by Application (2017-2028) Figure 66. Latin America Vaccine Conjugate Sales Share by Country (2017-2028) Figure 67. Latin America Vaccine Conjugate Revenue Share by Country (2017-2028) Figure 68. Mexico Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 69. Brazil Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 70. Argentina Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 71. Middle East and Africa Vaccine Conjugate Sales Market Share by Type (2017-2028) Figure 72. Middle East and Africa Vaccine Conjugate Revenue Market Share by Type (2017-2028) Figure 73. Middle East and Africa Vaccine Conjugate Sales Market Share by Application (2017-2028) Figure 74. Middle East and Africa Vaccine Conjugate Revenue Market Share by Application (2017-2028) Figure 75. Middle East and Africa Vaccine Conjugate Sales Share by Country (2017-2028) Figure 76. Middle East and Africa Vaccine Conjugate Revenue Share by Country (2017-2028) Figure 77. Turkey Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 78. Saudi Arabia Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 79. U.A.E Vaccine Conjugate Revenue (2017-2028) & (US$ Million) Figure 80. Vaccine Conjugate Value Chain Figure 81. Vaccine Conjugate Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

Pfizer GSK Sanofi Merck Walvax Biotechnology Royal (Wuxi) Bio-Pharmaceutical Bharat Biotech Zhifei Biologic